Avastin
E46087
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
Observed surface forms (2)
| Surface form | Occurrences |
|---|---|
| bevacizumab | 3 |
| VEGF-A | 1 |
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
anti‑angiogenic agent
ⓘ
biologic medicinal product ⓘ drug ⓘ monoclonal antibody ⓘ |
| antibodyIsotype | IgG1 ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
Food and Drug Administration ⓘ
surface form:
U.S. Food and Drug Administration
|
| belongsToCompanyPortfolio | Roche oncology portfolio ⓘ |
| commonAdverseEffect |
hemorrhage
ⓘ
hypertension ⓘ proteinuria ⓘ |
| contraindication |
recent major surgery
ⓘ
uncontrolled hypertension ⓘ |
| developedBy |
Genentech
ⓘ
Roche ⓘ |
| FDAApprovalYear | 2004 ⓘ |
| hasATCCode | L01FG01 ⓘ |
| hasDrugClass |
VEGF inhibitor
ⓘ
angiogenesis inhibitor ⓘ antineoplastic agent ⓘ |
| hasGenericName | bevacizumab ⓘ |
| hasINN |
Avastin
self-linksurface differs
ⓘ
surface form:
bevacizumab
|
| indicationType | oncology ⓘ |
| isBrandOf |
Avastin
self-linksurface differs
ⓘ
surface form:
bevacizumab
|
| isMonoclonalAntibodyType | humanized monoclonal antibody ⓘ |
| legalStatus | prescription only ⓘ |
| manufacturer |
Genentech
ⓘ
Roche ⓘ |
| mechanismOfAction |
inhibits angiogenesis by binding VEGF-A
ⓘ
prevents VEGF-A from binding to its receptors on endothelial cells ⓘ |
| oftenUsedInCombinationWith |
chemotherapy
ⓘ
fluorouracil‑based regimens ⓘ |
| origin | recombinant DNA technology ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| seriousAdverseEffect |
arterial thromboembolic events
ⓘ
gastrointestinal perforation ⓘ wound healing complications ⓘ |
| targets |
Avastin
self-linksurface differs
ⓘ
surface form:
VEGF-A
vascular endothelial growth factor A ⓘ |
| usedForTreatmentOf |
cervical cancer
ⓘ
epithelial ovarian cancer ⓘ fallopian tube cancer ⓘ glioblastoma ⓘ hepatocellular carcinoma (in combination regimens) ⓘ metastatic colorectal cancer ⓘ non‑small cell lung cancer ⓘ primary peritoneal cancer ⓘ renal cell carcinoma ⓘ |
Referenced by (6)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
bevacizumab